ClinicalTrials.gg
RecruitingNCT07036107Updated Jan 27, 2026

A Trial on the Clinical and Socioeconomic Impact of Wearable Exoskeletons for Spinal Cord Injury Rehabilitation in the Spanish Healthcare System

An interventional study of ABLE Exoskeleton and Conventional therapy in Spinal Cord Injury, sponsored by ABLE Human Motion S.L.. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Spinal Cord Injuries with a site in Spain — 11 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Planned enrollment
6th of 55
80 · median 30
Started
2026
with 4 others
No phase
34 of 59
8 open now
Primary completion
2027-09
later than 10 of 12 live
Registered
53rd of 59
by date
Lead sponsor
6 of 59
ABLE Human Motion S.L.

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 6th largest by planned enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2026, is one of 34 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 53rd registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

11 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

This clinical trial aims to collect evidence on the clinical benefits and the socioeconomic impact of integrating a novel wearable powered lower-limb exoskeleton for gait rehabilitation in acute/subacute spinal cord injured individuals and to evaluate the efficiency of this technology to the current standard of care in the Spanish Healthcare System (SNS).. The main questions it aims to answer are:

  • Is robotic therapy for gait rehabilitation more effective and efficient than conventional therapy?
  • Does robotic therapy for gait rehabilitation reduce the burden on healthcare professionals and caregivers?
  • Does robotic therapy for gait rehabilitation reduce direct healthcare costs?
  • Does robotic therapy for gait rehabilitation reduce intervention-related costs?

Researchers will compare a novel wearable powered lower-limb exoskeleton for gait rehabilitation to conventional therapy to see if the robotic exoskeleton is more effective and efficient in improving clinical benefits and to assess if it reduces the burden of healthcare professionals and caregivers, as well as healthcare and intervention-related costs.

Participants will:

  • Be randomized on a 1:1 basis to receive rehabilitation treatment with either the robotic exoskeleton or conventional therapy for gait recovery, 3 times a week on non-consecutive days for 8 weeks (24-session program).
  • Undergo a pre- and post-intervention assessment of clinical, functional, physiological, psychological, and socioeconomic variables.
  • Have a follow-up visit 2 months after the end of the treatment.
Read the detailed description

Participants will be recruited from among patients admitted to the institutions involved in the project: Vall d'Hebron University Hospital (HVH) through its research institute (VHIR) and the National Hospital for Paraplegics of Toledo (HNP), through its research foundation (FHNP). After checking the inclusion and exclusion criteria, informing the patient and signing the consent, they will be randomly distributed between the control group (CG) and the intervention group (IG). Open random parallel groups. The IG will receive rehabilitation treatment with the ABLE Exoskeleton, while the CG will receive conventional therapy for gait rehabilitation. The latter includes joint mobilizations, strengthening of paretic muscles and re-education of walking with parallel bars, making use of the technical aids and orthoses required by the patient (KAFOs, crutches and walkers). For both groups, participation in the study is based on a baseline visit, the 24-session rehabilitation treatment (including mid-training and end-training assessments at 12-session and 24-session, respectively) and a follow-up visit two months after the end of the treatment. Caregiver overload will also be assessed at baseline visit, after patient's treatment and at the follow-up visit two months after patient treatment.

03

Conditions studied

  • Spinal Cord Injury
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of spinal cord injury (SCI) in the acute or subacute phase (\< 6 months of evolution)
  • traumatic or non-traumatic aetiology
  • neurological level of the SCI between C5 and L5 for patients with American Spinal Injury Association Impairment Scale (AIS) C or D, and SCI between C7 and L5 for patients with AIS A or B.
  • sufficient strength in the upper extremities to handle a walker (triceps muscle score ≥ 4 according to the Medical Research Council (MRC) scale).
  • range of motion (ROM) without limitations in the lower extremities (achieve at least a knee extension of 10 degrees and neutral ankle position)
  • muscle spasticity in the lower extremities with a score ≤ 3 on the Modified Ashworth Scale (MAS)
  • tolerate bipedalism (having stood up in the last year)
  • aged between 18 and 70 years, with height between 150 cm and 190 cm, and weight less than 100 kg

Exclusion criteria

Exclusion Criteria:

  • WISCI ≥ 15
  • cognitive or neurological limitations that prevent following instructions
  • another neurologic disorder permanently affecting gait and gait therapy (other than SCI)
  • grade I or higher in the European Pressure Ulcer Advisory Panel (EPUAP) in the areas of contact with the exoskeleton
  • unresolved fractures at the time of the study
  • uncontrolled autonomic dysautonomia
  • intolerance to exercise
  • uncontrolled epilepsy
  • previous experience with Robotic-Assisted Gait Training (RAGT).
  • ROM restriction such as flexing or arthrodesis will be excluded
  • spinal instability (or spinal orthotics unless cleared by a medical doctor).
  • deterioration >3 points of the total in the motor score of the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) in the last 4 weeks. Loss of sensation and/or motor activity above the level of injury detected that has not been evaluated by a doctor.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Robotic exoskeleton

    The intervention group will receive rehabilitation treatment with the ABLE Exoskeleton

    Device: ABLE Exoskeleton

  • Active comparator
    Conventional therapy

    The control group will receive conventional therapy for gait rehabilitation

    Other: Conventional therapy

Interventions

  • DeviceABLE Exoskeleton

    Participants will receive a 24-session rehabilitation treatment program with the ABLE Exoskeleton, 3 times a week for up to 8 weeks

  • OtherConventional therapy

    Participants will receive a 24-session conventional therapy program for gait rehabilitation, 3 times a week for up to 8 weeks. Conventional therapy includes joint mobilizations, strengthening of paretic muscles and re-education of walking with parallel bars, making use of the technical aids and orthoses required by the patient (KAFOs, crutches and walkers).

06

What researchers measure

Primary outcomes

  1. Change in Walking ability

    The walking ability will be assessed using the Walking Index Spinal Cord Injury (WISCI) II which evaluates the amount of physical assistance needed, as well as devices required, for walking following paralysis that results from Spinal Cord Injury (SCI). The WISCI II score ranges from 0 to 20 (0: the individual is unable to walk, 20: the individual walks without assistance or devices)

    Time frame: Baseline , end of treatment (at 8 weeks), and follow-up (2 months after end of treatment)

  2. Change in Balance

    The balance will be assessed by the time taken to complete the Timed-Up-and-Go (TUG) test which evaluates mobility and balance.

    Time frame: Baseline, mid-training (at 4 weeks), and end of treatment (at 8 weeks)

  3. Change in Gait speed

    The gait speed will be assessed by the time taken to complete the 10 meter Walk Test (10mWT) which evaluates walking speed in meters per second over a short duration.

    Time frame: Baseline, mid-training (at 4 weeks), and end of treatment (at 8 weeks)

  4. Change in Lower Extremity Motor Score (LEMS)

    The Lower Extremity Motor Score (LEMS) evaluates motor function on a scale of 0 (no motor function) to 5 (full motor function) for 5 lower extremity muscle groups with a 50-point maximum (25 per side).

    Time frame: Baseline, mid-training (at 4 weeks), end of treatment (at 8 weeks), and follow-up (2 months after end of treatment)

  5. Change in Trunk control

    The trunk control will be assessed using the Trunk Assessment Scale for Spinal Cord Injury (TASS). The TASS consists of nine sitting tasks without upper-limb support: one task is static, and the other eight tasks are dynamic. Each item is assigned a score of 0-2, 0-4, or 0-6 for a total score of 44, with higher scores indicating better trunk function.

    Time frame: Baseline, end of treatment (at 8 weeks), and follow-up (2 months after end of treatment)

  6. Change in Endurance

    Endurance will be assessed by the distance (in meters) walked during the 2-Minute Walk Test (2MWT), which evaluates walking capacity and functional mobility.

    Time frame: Baseline, mid-training (at 4 weeks), and end of treatment (at 8 weeks)

  7. Change in Endurance

    Endurance will be assessed by the distance (in meters) walked during the 6-Minute Walk Test (6MWT), which evaluates walking capacity and functional mobility.

    Time frame: Baseline, mid-training (at 4 weeks), and end of treatment (at 8 weeks)

  8. Change in Level of Exertion

    Perceived exertion associated with the walking test (2MWT/6MWT) will be assessed using the Borg Rating of Perceived Exertion Scale, a self-report scale ranging from 0 to 10. A score of 0 indicates no exertion, and 10 indicates maximal exertion. Higher scores represent greater perceived exertion.

    Time frame: Baseline, mid-training (at 4 weeks), and end of treatment (at 8 weeks)

  9. Change in Gait pattern

    The gait pattern and compensatory movements will be assessed through kinetic and kinematic gait parameters collected using a 3-D gait analysis system. The Gait Deviation Index for SCI (SCI-GDI) will be calculated to evaluate the difference between the patient' gait pattern compared to the reference gait pattern. The SCI-GDI score typically ranges from 0 to 100, with 100 representing a normal gait pattern.

    Time frame: Baseline, mid-training (at 4 weeks), end of treatment (at 8 weeks), and follow-up (2 months after end of treatment)

  10. Change in Bladder and Bowel function

    Bladder and bowel function will be assessed using the International Standards to document Autonomic Function following SCI (ISAFSCI), which identifies which autonomic functions (e.g., bladder, bowel) are intact, impaired, or lost.

    Time frame: Baseline, end of treatment (at 8 weeks), and follow-up (2 months after end of treatment)

  11. Change in Bladder and Bowel function

    Bowel function will also be assessed using the Neurogenic Bowel Dysfunction score (NBD score), a self-report questionnaire. The total NBD score ranges from 0 to 47, with higher scores indicating more severe dysfunction.

    Time frame: Baseline, end of treatment (at 8 weeks), and follow-up (2 months after end of treatment)

  12. Change in Bone density

    The Bone density will be assessed through analytical control, 24-hour urine, and dual-energy X-ray absorptiometry (DEXA) scan in the spine, hip and knee.

    Time frame: At baseline and end of treatment (at 8 weeks)

  13. Change in Cardiovascular function

    The cardiovascular function will be asssessed by an arm ergometry test, which is a test that measures the heart's response to physical exertion. The maximum heart rate (HR) will be documented.

    Time frame: At baseline and end of treatment (at 8 weeks)

  14. Change in Respiratory function

    The respiratory function will be assessed by a simple spirometry, which is a test that measures the volume of air exhaled in one second (FEV1) and the total volume of air exhaled forcefully (FVC).

    Time frame: Baseline, end of treatment (at 8 weeks), and follow-up (2 months after end of treatment)

  15. Pain reduction

    The reduction in pain will be assessed using International Spinal Cord Injury Pain Basic Data Set (ISCIPBDS) which is used to document the interference of pain with physical and emotional function and sleep, probable pain diagnosis, location, intensity and duration. Each value is scored on a 0 to 10 numerical rating scale, where 0 represents no pain and 10 represents the worst pain imaginable.

    Time frame: From baseline to follow-up (at 2 months after the end of treatment)

  16. Change in Spasticity

    The spasticity in the lower limbs will be assessed using both the Spinal Cord Assessment Tool for Spastic Reflexes (SCATS) score, which evaluates three types of spastic motor behaviors in SCI patients - clonus, flexor spasms, and extensor spasms, as well as the Modified Ashworth Scale (MAS). SCATS total score (0-9; higher = worse outcome)

    Time frame: Baseline, end of treatment (at 8 weeks), and follow-up (2 months after the end of treatment)

  17. Change in Functional independence

    The functional independence will be assesed using the Spinal Cord Independence Measure III (SCIM III) which is a patient-reported outcome measure that evaluates three main domains: self-care, respiration and sphincter management, and mobility. The SCIM III score is calculated on a scale of 0-100, with 0 indicating complete dependence and 100 indicating complete independence.

    Time frame: Baseline, end of treatment (at 8 weeks), and follow-up (2 months after the end of treatment)

  18. Change in Quality of Life

    Quality of life will be assessed using the 5-level EQ-5D version (EQ-5D-5L), a standardized instrument for measuring generic health status. Ranging from 1 (best possible health) to values less than 0.

    Time frame: At baseline and end of treatment (at 8 weeks)

  19. Change in Quality of Life

    Emotional well-being will be assessed using the Hospital Anxiety and Depression Scale (HADS), which measures anxiety and depression. Score on HADS subscales (0-21 per subscale; with higher numbers indicating a greater level of anxiety or depression)

    Time frame: At baseline and end of treatment (at 8 weeks)

  20. Change in Quality of Life

    Motivation will be assessed using the interest/enjoyment subscale of the Intrinsic Motivation Inventory (IMI). Interest/Enjoyment score on IMI subscale (1-7; where 1 represents "Not at all true" and 7 represents "Very true")

    Time frame: At baseline and end of treatment (at 8 weeks)

  21. Burden of healthcare professionals

    The burden on healthcare professionals will be assessed using the NASA Task Load Index (NASA-TLX), a self-report questionnaire to assess work load on five 7-point scales. NASA-TLX scores can range from 0 to 100, where a higher score generally indicates a higher workload

    Time frame: At end of treatment (8 weeks)

  22. Change in Burden of the caregiver

    The caregiver burden will be assessed using the Zarit Burden Interview, a 22-item self-report questionnaire which total score ranges from 0 to 88. The higher the value, the higher the caregiver burden.

    Time frame: Baseline, end of treatment (at 8 weeks), and follow-up (2 months after the end of treatment)

  23. Change in Direct healthcare costs

    The medical costs including hospitalization days, transportations, specialists consultations, rehabilitation services, emergency room visits, and hospital admissions will be calculated.

    Time frame: Baseline (Day 0), end of treatment (8 weeks), and follow-up (16 weeks)

  24. Intervention-related costs

    The costs associated to the rehabilitation sessions, treatment, and equipment during the intervention period will be calculated.

    Time frame: At the end of treatment (8 weeks)

  25. Change in the productivity losses

    Variation in indirect costs for patient and caregiver, associated with reduced work capacity, absenteeism, or early retirement, as a result of the intervention.

    Time frame: Baseline, end of treatment (at 8 weeks), and follow-up (2 months after the end of treatment)

07

Study locations

1 of 2 sites recruiting
  • Hospital Nacional de Parapléjicos
    Toledo, Castille-La Mancha 45071, Spain
    Not yet recruiting
    • Ana de los Reyes Guzmán, PhD · Contactadlos@sescam.jccm.es · 925247771
    • Ana de los Reyes Guzmán, PhD · Principal investigator
  • Hospital Universitario de Vall d'Hebron
    Barcelona, Catalonia 08035, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2027, 20 months after the start.

Of 49 industry-sponsored interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 20 months is above that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 25, 2025
StartActual
Jan 15, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07036107
Lead sponsor
ABLE Human Motion S.L.
Collaborators
Hospital Nacional de Parapléjicos de Toledo, Universitat de Lleida, Hospital Universitari Vall d'Hebron Research Institute
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Jan 15, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Jan 27, 2026

Study contacts

Lluïsa Montesinos Magraner, Dr
Contact
lluisa.montesinos@vallhebron.cat
+34 620951308
Lluïsa Montesinos Magraner, Dr
principal investigator · Hospital Universitario de Vall d'Hebron
Ana de los Reyes Guzmán, PhD
principal investigator · Hospital Nacional de Parapléjicos

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion